GRI Bio, Inc. Files S-1/A for Securities Registration

Ticker: GRI · Form: S-1/A · Filed: Mar 26, 2025 · CIK: 1824293

Sentiment: neutral

Topics: securities-offering, pharmaceuticals, filing-update

TL;DR

GRI Bio (formerly Vallon Pharma) filed S-1/A for stock offering. Watch for funding news.

AI Summary

GRI Bio, Inc. filed an S-1/A on March 26, 2025, to register securities. The company, formerly known as Vallon Pharmaceuticals, Inc. and GRI BIO, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector. Its principal executive offices are located in La Jolla, California.

Why It Matters

This filing indicates GRI Bio, Inc. is preparing to offer securities to the public, which could lead to new funding for its operations or expansion, potentially impacting its stock and future development.

Risk Assessment

Risk Level: medium — As an S-1/A filing, it pertains to a securities offering, which inherently carries risks related to market reception and company valuation.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this S-1/A filing?

The S-1/A filing by GRI Bio, Inc. on March 26, 2025, is for the registration of securities.

What were the previous names of GRI Bio, Inc.?

GRI Bio, Inc. was formerly known as GRI BIO, Inc. (name change on 20230424) and prior to that, Vallon Pharmaceuticals, Inc. (name change on 20200910).

Where is GRI Bio, Inc. located?

GRI Bio, Inc.'s business and mail address is 2223 Avenida De La Playa, Suite 208, La Jolla, CA 92037.

What industry does GRI Bio, Inc. operate in?

GRI Bio, Inc. operates in the Pharmaceutical Preparations sector, as indicated by its Standard Industrial Classification (SIC) code 2834.

When was the company incorporated?

GRI Bio, Inc. was incorporated in Delaware (DE).

Filing Details

This Form S-1/A (Form S-1/A) was filed with the SEC on March 26, 2025 regarding GRI Bio, Inc. (GRI).

View full filing on EDGAR

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing